US equities |
MU $1,029.00 ▼-0.66% NVDA $229.28 ▼-0.52% SPCX $162.57 ▲+1.25% TSLA $382.70 ▲+2.05% AAPL $336.64 ▼-1.11% MSFT $535.07 ▲+2.38% AMZN $262.43 ▲+3.29% META $718.67 ▼-0.31%
FinancialContent

Articles published by Avacta Group PLC

News headline image
Avacta Group plc: Interim Results for the Six Months to June 30, 2026, and Business Update
From Avacta Group PLC
Via GlobeNewswire
Tickers LSE
News headline image
Avacta Group plc: The FOCUS-01 Clinical Trial Design and Preclinical Data Further Demonstrate the Potential of AVA6103 at AACR Conference on Pancreatic Cancer
From Avacta Group PLC
Via GlobeNewswire
Tickers LSE
News headline image
Avacta Achieves Clinical Proof of Mechanism for the Next Generation of pre|CISION® Medicines with AVA6103 (FAP-Exd) in the Phase 1 FOCUS-01 Trial
From Avacta Group PLC
Via GlobeNewswire
Tickers LSE
News headline image
Avacta Appoints Mats Blom to the Board of Directors as Chair of Audit Committee
From Avacta Group PLC
Via GlobeNewswire
Tickers LSE
News headline image
Avacta Appoints Healthcare Executive Patrick Vink as Deputy Chairman of the Board of Directors
From Avacta Group PLC
Via GlobeNewswire
Tickers LSE
News headline image
Avacta presents updated clinical data showing encouraging early efficacy signals for AVA6000 in salivary gland cancers at ASCO 2026
From Avacta Group PLC
Via GlobeNewswire
Tickers LSE
News headline image
Unaudited Preliminary Results for the Year Ended December 31, 2025
From Avacta Group PLC
Via GlobeNewswire
Tickers LSE
News headline image
Avacta presents new comparisons of pre|CISION® payload release vs approved ADCs and AVA6207 dual payload delivery at Science Day 2026
From Avacta Group PLC
Via GlobeNewswire
Tickers LSE
News headline image
Avacta data at AACR 2026 underline favorable profile of AVA6103 and advantages of pre|CISION® delivery platform
From Avacta Group PLC
Via GlobeNewswire
Tickers LSE
News headline image
Avacta CEO Christina Coughlin Named as One of In Vivo's 2026 Rising Leaders
From Avacta Group PLC
Via GlobeNewswire
Tickers LSE
News headline image
Avacta announces first patient treated in Phase 1 FOCUS-01 trial of FAP-Exd (AVA6103) - a sustained-release pre|CISION® exatecan peptide drug conjugate
From Avacta Group PLC
Via GlobeNewswire
Tickers LSE
News headline image
Avacta Announces Preclinical and Translational Presentations of pre|CISION® Platform Candidates at the 2026 AACR Annual Conference
From Avacta Group PLC
Via GlobeNewswire
Tickers LSE
News headline image
Avacta's pre|CISION Mechanism for Payload Delivery Shows Key Advantages Compared to an Antibody Drug Conjugate in Innovative AI-Driven Analysis
From Avacta Group PLC
Via GlobeNewswire
Tickers LSE
News headline image
Avacta appoints Francis Wilson as Chief Scientific Officer
From Avacta Group PLC
Via GlobeNewswire
Tickers LSE
News headline image
Avacta Announces Two Key Clinical Updates to its Faridoxorubicin Program
From AVACTA GROUP PLC
Via GlobeNewswire
Tickers LSE
News headline image
Avacta Announces U.S. Food and Drug Administration Clearance of the Investigational New Drug (IND) Application for the Second pre|CISION® Medicine, FAP-Exatecan (AVA6103)
From AVACTA GROUP PLC
Via GlobeNewswire
Tickers LSE
News headline image
Avacta Announces Year-end Trading Update
From AVACTA GROUP PLC
Via GlobeNewswire
Tickers LSE
News headline image
Faridoxorubicin (AVA6000) Phase 1b cohort demonstrates clinically meaningful tumor shrinkage in patients with salivary gland cancers
From AVACTA GROUP PLC
Via GlobeNewswire
Tickers LSE
News headline image
Avacta presents first preclinical data from dual payload pre|CISION® medicines at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets
From AVACTA GROUP PLC
Via GlobeNewswire
Tickers LSE
News headline image
Avacta Therapeutics Presents Compelling Phase 1a Data for Faridoxorubicin and the pre|CISION® Platform at the European Society of Medical Oncology Annual Congress
From AVACTA GROUP PLC
Via GlobeNewswire
Tickers LSE
News headline image
Avacta to Present First Dual Payload pre|CISION® Medicines Data at the 2025 EORTC-NCI-AACR International Conference on Molecular Targets Symposium
From AVACTA GROUP PLC
Via GlobeNewswire
Tickers LSE
News headline image
Avacta to Present New FAP Dox (AVA6000) Data at the European Society for Medical Oncology (ESMO) Congress
From AVACTA GROUP PLC
Via GlobeNewswire
Tickers LSE
News headline image
Avacta Appoints David Liebowitz, M.D., Ph.D. as Chief Medical Officer and Yulii Bogatyrenko as Advisor in Business Development
From AVACTA GROUP PLC
Via GlobeNewswire
Tickers INO LSE
News headline image
Avacta Therapeutics Announces Appointments of Industry Veterans to Board of Directors
From AVACTA GROUP PLC
Via GlobeNewswire
Tickers LSE
News headline image
Avacta Therapeutics Presents Data from Lead pre|CISION® Candidate FAP-Dox (AVA6000) at the 2025 AACR Annual Meeting
From AVACTA GROUP PLC
Via GlobeNewswire
Tickers LSE
News headline image
Avacta Therapeutics Presents Preclinical and Translational Data from pre|CISION® Platform Candidates at 2025 AACR Annual Meeting
From AVACTA GROUP PLC
Via GlobeNewswire
Tickers LSE
News headline image
Avacta Provides Business Update for the First Quarter of 2025 Outlining Progress Against Strategic Objectives
From AVACTA GROUP PLC
Via GlobeNewswire
Tickers LSE
News headline image
Avacta Therapeutics Announces Presentations at 2025 AACR Annual Meeting
From AVACTA GROUP PLC
Via GlobeNewswire
Tickers LSE
News headline image
Avacta Therapeutics to Present at the 2025 Leerink Global Healthcare Conference
From AVACTA GROUP PLC
Via GlobeNewswire
Tickers LSE
News headline image
Avacta Announces Promising Early Efficacy and Safety Data for AVA6000 in the Phase 1a Dose Escalation and Ongoing Enrollment in the Phase 1b Expansion Cohorts
From AVACTA GROUP PLC
Via GlobeNewswire
Tickers LSE